SpecialtiesChong-Xian Pan, M.D. 
Clinical/Research Interests
Title:
Specialty:
Center/Program Affiliation:
Address:
4501 X St., Suite 2nd floor
Sacramento, CA 95817
Phone:
Other Languages:
Education:
Shanghai,
M.D. 1989
Internships:
Evanston, IL
1999
Residency:
Evanston, IL
2002
Internal Medicine
Fellowships:
Indiapolis, IN
2005
Hematology/Oncology
Board Certifications:
American Board of Internal Medicine, 2002
Professional Memberships:
American Society of Clinical Oncology
Honors and Awards:
The American Society of Clinical Oncology Foundation Merit Award, 2004
The Resident Scholarship from the American College of Physicians-American Society of Internal Medicine, 2002
The University Fellowship, Loyola University, 1998-1999
Travel Grant, from the joint meeting of the American Association for Cancer Research and the Japanese Cancer Association: “Innovative Molecular Biology Approaches to the Prevention, Diagnosis and Therapy of Cancer.", 1998
Travel Award, the American Society of Hematology, 1995
Select Recent Publications:
Lin TY, Zhang H, Wang S, Xie L, Li B, Rodriguez CO Jr, de Vere White R, Pan CX. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol Cancer. 2011 Jan 27;10(1):9.
Vinall RL, Zripoll A, Wang S, Pan CX, Devere White RW. MiR-34a chemo-sensitizes bladder cancer cells to cisplatin treatment regardless of P53-Rb pathway status. Int J Cancer. 2011 Jun 23. doi: 10.1002/ijc.26256.
Cheng L, Zhang S, Alexander R, Yao Y, MacLennan GT, Pan CX, Huang J, Wang M, Montironi R, Lopez-Beltran A. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncol. 2011 Apr;7(4):519-41.
Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN Jr. A phase II trial of gefitinib and pegylated IFNa in previously treated renal cell carcinoma. Int J Clin Oncol. 2011 Oct;16(5):494-9. Epub 2011 Mar 23.
Cheng L, Alexander R, Zhang S, Pan CX, MacLennan GT, Lopez-Beltran A, Montironi R. The clinical and therapeutic implications of cancer stem cell biology. Expert Rev Anticancer Ther. 2011 Jul;11(7):1131-43.
Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer. 2011 Sep 15;129(6):1425-34. doi: 10.1002/ijc.25814. Epub 2011 Mar 4.
Henderson PT, Pan CX. Human microdosing for the prediction of patient response. Bioanalysis. 2010 Mar;2(3):373-6.
Sandhu R, Pan CX, Wun T, Harvey D, Zhou H, White RH, Chew HK. The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer. 2010 Jun 1;116(11):2596-603.
Wang S, Zhang H, Malfatti M, de Vere White R, Lara PN Jr, Turteltaub K, Henderson P, Pan CX. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem Res Toxicol. 2010 Nov 15;23(11):1653-5. Epub 2010 Oct 28.
Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol Oncol. 2010 Sep 29.
